Company Filing History:
Years Active: 2021-2024
Title: Linda Veronique Kazandjian: Innovator in Humanized Antibodies
Introduction
Linda Veronique Kazandjian is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of two patents to her name, her work focuses on innovative treatments for IL-1R3 mediated diseases, including cancer.
Latest Patents
Kazandjian's latest patents involve humanized anti-IL-1R3 antibodies. These inventions relate to antibodies that specifically bind to IL-1R3 or its fragments, which are crucial for inhibiting IL-1R3 induced NFkB activity. The antibodies also inhibit the activity stimulated by IL-1alpha, IL-1beta, IL-33, and IL-36. Furthermore, her patents encompass pharmaceutical compositions that include a therapeutically effective amount of these antibodies, aimed at treating IL-1R3 mediated diseases such as cancer.
Career Highlights
Throughout her career, Kazandjian has worked with notable companies, including Sanofi Biotechnology and Sanofi Biotechnology Sas. Her expertise in biotechnology has allowed her to contribute to groundbreaking research and development in the field.
Collaborations
Kazandjian has collaborated with esteemed colleagues such as Stephan Fischer and Michael Brandt. These partnerships have further enhanced her research and innovation in the biotechnology sector.
Conclusion
Linda Veronique Kazandjian is a trailblazer in the field of humanized antibodies, with her innovative patents paving the way for new treatments for serious diseases. Her contributions to biotechnology continue to have a significant impact on medical research and therapeutic development.